home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  CHI's Strategies and Structures to Optimize R&D Performance  
  February 12, 2003

Biotechnology

 
     
  Cambridge Healthtech Institute, Wyndham Franklin Plaza Hotel, 17th & Race Streets, Philadelphia, PA
June 9-10, 2003


There are revolutionary changes happening in the pharmaceutical industry. Billions of dollars are at stake. Pharmaceutical companies must start investing resources to create an organizational structure that will support the new processes needed to reduce the time from target identification to clinical trials. Partial List of Confirmed Speakers

Dr. Michael Liebman, Abramson Cancer Center of the University of Pennsylvania
Arjun Bedi, Accenture

Dr. Otto Ritter, AstraZeneca R&,D

David Steward, Aventis SA

John Murphy, CuraGen

Dr. Rainer Fuchs, Biogen, Inc.

Dr. Frank Wang, Boehringer Ingelheim

Osagie O. Imasogie, GlaxoSmithKline

Sven Blumenstiel, IBM Business Consulting Services

Dr. Vanessa Lum, Johnson & Johnson

Dr. Samuel Holtzman, Rosa Pharmaceuticals

Dr. Jack Pollard, 3rd Millennium Inc.

Dr. Alan Dunton


Create interfaces across departments to optimize the R&D process
How to make new processes and technologies work
Impact of change due to mergers and acquisitions on R&D project and process management
Locate information bottlenecks and apply processes to expedite the flow of information
Recognize attrition at earlier phases

Pre-Conference Tutorial
Maximizing Pipeline Value:
Know Your Market and Fail Fast
Dr. Samuel Holtzman, Cofounder, Chairman, President and CEO, Rosa Pharmaceuticals
David Steward, Director of Technology Licensing & Acquisitions, Aventis SA
Dr. Alan Dunton, Former President, Janssen Research Foundation

 
 
Organized by: Cambridge Healthtech Institute
Invited Speakers: Dr. Michael Liebman, Abramson Cancer Center of the University of Pennsylvania
Arjun Bedi, Accenture

Dr. Otto Ritter, AstraZeneca R&,D

David Steward, Aventis SA

John Murphy, CuraGen

Dr. Rainer Fuchs, Biogen, Inc.

Dr. Frank Wang, Boehringer Ingelheim

Osagie O. Imasogie, GlaxoSmithKline

Sven Blumenstiel, IBM Business Consulting Services

Dr. Vanessa Lum, Johnson & Johnson

Dr. Samuel Holtzman, Rosa Pharmaceuticals

Dr. Jack Pollard, 3rd Millennium Inc.

Dr. Alan Dunton

 
Deadline for Abstracts: n/a
 
Registration: Available Online fax: 617-630-1325 call:617-630-1300
E-mail: chi@healthtech.com
 
  Posted by:   elaine eskedal  
Host: wks152.healthtech.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.